What question did this study set out to answer?

The aim is to evaluate the efficacy of GM-DM1 in targeting leukemia stem cells in acute myeloid leukemia while minimizing toxicity.

December 8, 2025Blood

Long-acting GM-CSF-based drug conjugate effectively targets leukemia stem cells in Acute Myeloid Leukemia with limited toxicity

View Full Paper

Ask AI

Bookmark

Authors

This therapeutic targeting approach enhances cytotoxicity and may reduce off-target toxicity in AML.

The aim is to evaluate the efficacy of GM-DM1 in targeting leukemia stem cells in acute myeloid leukemia while minimizing toxicity.
Developed GM-DM1, a GM-CSF-based drug conjugate with a microtubule inhibitor.
Evaluated GM-DM1's effects on leukemia stem cells in vitro and in vivo.
Assessed cytotoxicity, apoptosis induction, and off-target effects using various AML models.
GM-DM1 induced significant cytotoxicity and apoptosis in leukemia cells while sparing healthy cells.
It demonstrated reduced leukemic burden in patient-derived xenograft models.
Off-target toxicity was minimal, preserving normal hematopoietic cell function.

Xiao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark